"The concern is not just about what the Trump 2.0 Administration will do, but also about what it will say," writes .

Moderna Inc.'s stock was higher but off its early highs Thursday, after the company's third-quarter earnings showed an unexpected profit as well as revenue that beat estimates by a wide margin. The ...

Moderna reported better third-quarter results than expected Thursday morning, as the vaccine maker reported a surprise profit for the period amid its efforts to cut costs and $1.8 billion in sales of ...

Moderna (MRNA) got a boost in the third quarter from an earlier US approval of its updated COVID-19 vaccine, underpinning sales growth and helping drive a surprise net income result at the drugmaker.

Moderna surprised Wall Street with a third-quarter profit on Thursday, driven by robust COVID-19 vaccine sales and ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its COVID-19 vaccine, even with low revenue from its new respiratory syncytial ...

Moderna stock rises as Q3 revenue beats estimates at $1.83 billion, driven by strong U.S. COVID-19 vaccine sales. EPS of $0.03 exceeds expectations.

Moderna (MRNA) stock gains as company posts better than expected Q3 results driven by its updated COVID-19 vaccine. Read more ...

Moderna Chief Human Resources Officer Tracey Franklin has expanded her role to Chief People and Digital Technology Officer, overseeing the Company's talent and digital functions. Brad Miller, Chief ...

Journey Medical said the agency approved its drug for the treatment of a long-term skin condition called rosacea. The FDA ...